Pharminho: Pharma Regulatory

Vaayath Infotech Pvt. Ltd.

About this app

Pharminho is a Independent Pharma regulatory app for India. Check drug approval status, search a database of 15,000+ drugs, follow the upcoming drug pipeline, read Pharma news, and get expert regulatory consulting — all in one place.
Made for regulatory affairs, R&D and QA professionals, Pharminho turns scattered regulatory lookups into a single, searchable drug database.
Whether you're planning a dossier, tracking a submission or checking where a drug stands with the authorities, the answer is a search away.

KEY FEATURES

• Drug repository — 15,000+ drugs with approval status, status date and category

• Upcoming drugs — regulatory details for drugs in the pipeline

• Services catalogue — custom solutions from our regulatory consulting team

• Medical Devices, IVD & Non-Sterile Devices module
• Pharma blog — regularly updated CDSCO and industry regulatory news

• Bookmarks and tracking to organise your work

DRUG REPOSITORY:
 Search any drug by name and open its regulatory profile. Pro members see deeper detail — strengths & compositions, indications, official approval letters, approval pathway, applicant details and license checklists.

UPCOMING DRUGS: 
Follow drugs under review with CDSCO and other authorities, their current stage and applicant details, so your team can plan ahead.

EXPERT SERVICES: 
Request services such as global approval status (USFDA, EMA, MHRA, TGA), personalized regulatory assessments, custom approval pathways and market research reports. Our team typically responds in 2–3 working days.

MEDICAL DEVICES & DIAGNOSTICS: 
A dedicated module for Medical Devices, In Vitro Diagnostics (IVD) and Non-Sterile Devices is on the way, extending Pharminho's regulatory coverage to device professionals.

PRO MEMBERSHIP & WALLET: 
Unlock restricted regulatory insights and consulting services with a Pro membership — plans from 1 month to 3 years, with larger savings on longer terms. Top up your VCash wallet to pay for services, and track every service and transaction in one view.

WHO USES PHARMINHO: 
Regulatory affairs specialists, dossier and submission planners, pharmaceutical R&D and QA teams, and compliance professionals.

Available in India (₹) and internationally ($).

DISCLAIMER: 
Pharminho is an independent, privately operated app. We are not affiliated with, endorsed by, or associated with CDSCO, DCGI, USFDA, EMA, or any other government body, regulatory authority, or official agency. Any references to such authorities are for informational purposes only.
While we strive to keep the information on Pharminho as accurate and up to date as possible, we make no representation or warranty of any kind regarding its completeness, accuracy, reliability, or timeliness. All information is provided "as is" for general reference only and should not be treated as legal, regulatory, or professional advice. Users are responsible for independently verifying any information before relying on it. To the fullest extent permitted by law, Pharminho and its operators accept no liability or accountability for any loss, damage, or consequence arising from the use of, or reliance on, any information available through the app.
Support: [e-mail]

Pharminho is an independent platform and is not affiliated with, endorsed by, or associated with any government authority or regulatory body.

Pharminho – Independent Pharmaceutical Regulatory Information Platform

Data Sources (Official Public Websites):

Central Drugs Standard Control Organization (CDSCO)
https://cdsco.gov.in/

CDSCO Online Portal
https://cdscoonline.gov.in/

U.S. Food and Drug Administration (FDA)
https://www.fda.gov/

European Medicines Agency (EMA)
https://www.ema.europa.eu/

All information is sourced from publicly accessible official websites and presented in an organized format for user convenience.

What’s new

What’s New 1.3.7

Faster app startup with improved cold start performance.
Fixed the reset password issue.
Improved the Blog Details UI and user experience.
General bug fixes and performance improvements.